文献速递心律失常

院外难治性心脏骤停:静脉与骨内途径抗心律失常药物生存分析

Survival After Intravenous Versus Intraosseous Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refractory Cardiac Arrest.
PubMed 文献 · Circulation · 2020-01-16

该研究为ALPS试验预设分析,比较静脉与骨内途径给予胺碘酮、利多卡因或安慰剂对院外难治性室颤/无脉性室速成人患者出院生存的影响。结果显示静脉胺碘酮和利多卡因较安慰剂显著提高出院生存,而骨内途径无显著获益;药物途径交互作用未达统计学显著,研究把握度不足。

要点

  • 静脉胺碘酮较安慰剂提高出院生存(校正RR 1.26,95%CI 1.06-1.50)。
  • 静脉利多卡因较安慰剂提高出院生存(校正RR 1.21,95%CI 1.02-1.45)。
  • 骨内胺碘酮或利多卡因较安慰剂无显著生存获益。

核心结论

  • 静脉给予胺碘酮或利多卡因较安慰剂显著提高出院生存,骨内途径无显著获益。
  • 药物途径交互作用未达统计学显著,研究把握度不足。

研究设计与样本

  • ALPS随机安慰剂对照试验的预设分析,纳入3019例已知血管通路部位的院外难治性室颤/无脉性室速成人患者。
  • 2358例经静脉给药,661例经骨内给药。

主要发现

  • 总体出院生存率为23%。
  • 静脉胺碘酮较安慰剂:校正风险比1.26(95%CI 1.06-1.50),校正绝对生存差异5.5%(95%CI 1.5-9.5)。
  • 静脉利多卡因较安慰剂:校正风险比1.21(95%CI 1.02-1.45),校正绝对生存差异4.7%(95%CI 0.7-8.8)。
  • 骨内胺碘酮较安慰剂:校正风险比0.94(95%CI 0.66-1.32);骨内利多卡因:校正风险比1.03(95%CI 0.74-1.44)。
  • 静脉给药组入院生存率亦显著提高,骨内给药组无显著提高,且静脉给药倾向于改善出院神经功能结局。

临床怎么用

  • 院外难治性室颤/无脉性室速复苏时,若建立静脉通路,可考虑静脉给予胺碘酮或利多卡因以改善生存。
  • 骨内途径给予胺碘酮或利多卡因未显示生存获益,选择给药途径时需考虑此差异。

局限性

  • 研究把握度不足以评估静脉/骨内药物交互作用,交互作用未达统计学显著。
  • 静脉与骨内组在性别、EMS到达时间及部分CPR特征上存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antiarrhythmic drugs have not proven to significantly improve overall survival after out-of-hospital cardiac arrest from shock-refractory ventricular fibrillation/pulseless ventricular tachycardia. How this might be influenced by the route of drug administration is not known. METHODS: In this prespecified analysis of a randomized, placebo-controlled clinical trial, we compared the differences in survival to hospital discharge in adults with shock-refractory ventricular fibrillation/pulseless ventricular tachycardia out-of-hospital cardiac arrest who were randomly assigned by emergency medical services personnel to an antiarrhythmic drug versus placebo in the ALPS trial (Resuscitation Outcomes Consortium Amiodarone, Lidocaine or Placebo Study), when stratified by the intravenous versus intraosseous route of administration. RESULTS: Of 3019 randomly assigned patients with a known vascular access site, 2358 received ALPS drugs intravenously and 661 patients by the intraosseous route. Intraosseous and intravenous groups differed in sex, time-to-emergency medical services arrival, and some cardiopulmonary resuscitation characteristics, but were similar in others, including time-to-intravenous/intrasosseous drug receipt. Overall hospital discharge survival was 23%. In comparison with placebo, discharge survival was significantly higher in recipients of intravenous amiodarone (adjusted risk ratio, 1.26 [95% CI, 1.06-1.50]; adjusted absolute survival difference, 5.5% [95% CI, 1.5-9.5]) and intravenous lidocaine (adjusted risk ratio, 1.21 [95% CI, 1.02-1.45]; adjusted absolute survival difference, 4.7% [95% CI, 0.7-8.8]); but not in recipients of intraosseous amiodarone (adjusted risk ratio, 0.94 [95% CI, 0.66-1.32]) or intraosseous lidocaine (adjusted risk ratio, 1.03 [95% CI, 0.74-1.44]). Survival to hospital admission also increased significantly when drugs were given intravenously but not intraosseously, and favored improved neurological outcome at discharge. There were no outcome differences between intravenous and intraosseous placebo, indicating that the access route itself did not demarcate patients with poor prognosis. The study was underpowered to assess intravenous/intraosseous drug interactions, which were not statistically significant. CONCLUSIONS: We found no significant effect modification by drug administration route for amiodarone or lidocaine in comparison with placebo during out-of-hospital cardiac arrest. However, point estimates for the effects of both drugs in comparison with placebo were significantly greater for the intravenous than for the intraosseous route across virtually all outcomes and beneficial only for the intravenous route. Given that the study was underpowered to statistically assess interactions, these findings signal the potential importance of the drug administration route during resuscitation that merits further investigation.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Daya MR, Leroux BG, Dorian P, et al. Survival After Intravenous Versus Intraosseous Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refractory Cardiac Arrest. Circulation. 2020. PMID: 31941354. doi:10.1161/CIRCULATIONAHA.119.042240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。